GLP-1 prescription trend statistics in the US for 2026

What the use statistics do and avoid show

Gallup reported that 11% of US adults were currently taking a GLP-1 medicine for weight loss in its May to June 2026 survey. That rose from 3% in 2024. Gallup also found that 15% had ever used one, which includes people who may have stopped, switched medicines, or used treatment for a limited period. These are self-reported use estimates, not pharmacy dispensing totals. The United States does not publish one live public count that combines prescriptions, fills, cash purchases, insurance claims, and compounded products. Treating those measures as interchangeable would make the trend look more precise than the data allow.

Why the trend changes everyday treatment decisions

For people with type 2 diabetes, GLP-1 medicines have been part of care for years. CDC estimated that 6.9 million adults with diagnosed diabetes used an injectable GLP-1 in 2024. The visible expansion in 2026 is happening alongside weight-management choices, including Wegovy, Zepbound, and Foundayo. A choice may involve more than a weekly injection versus a daily tablet. It can turn on the FDA-approved reason for use, diabetes medicines that may affect low blood sugar risk, digestive history, plans for surgery or sedation, pregnancy planning where relevant, and how reliably a person can obtain refills. A clinician and pharmacist can help separate an active ingredient from a brand's specific approved use and label.

What weight-loss trials may mean for you

Trial averages are useful for setting expectations, not predicting an individual's result. Participants had defined eligibility criteria, scheduled follow-up, lifestyle support, and a supply of treatment. People also varied widely around the average. In STEP 1, adults without diabetes taking semaglutide 2.4 milligrams with lifestyle intervention lost an average 14.9% of starting weight at 68 weeks, compared with 2.4% with placebo. At a starting weight of 220 pounds, 14.9% is about 33 pounds on average. About 69% lost at least 10% and about 51% lost at least 15%. In SURMOUNT-1, adults without diabetes taking tirzepatide 15 milligrams lost an average 20.9% at 72 weeks, versus 3.1% with placebo. For a 220-pound person, that percentage is about 46 pounds. SURMOUNT-1 and STEP 1 were separate studies, so their averages should not be treated as a direct drug-versus-drug result. For oral orforglipron, sold as Foundayo, Lilly reported 11.1% average loss at 72 weeks in the treatment-policy analysis of ATTAIN-1, compared with 2.1% with placebo. The company also reported 12.4%, or 27.3 pounds, among participants at the highest dose who stayed on treatment. The distinction matters because trial completion and treatment continuation affect the result being described.

Coverage and cost are still the practical barrier

An advertised price is not necessarily the amount a person pays. Deductibles, coinsurance, plan exclusions, pharmacy choice, prior authorization, and savings-offer terms can all change the final amount. Commercial savings offers commonly exclude government-insured patients. Novo Nordisk listed a Wegovy tablet self-pay starting price of $149 per month for certain doses. Its introductory injection offer was $199 per month for the first two monthly fills, then a stated $349 per month for listed standard doses. Lilly listed Zepbound self-pay options from $299 to $449 per month and Foundayo from $149 per month at the lowest tablet strength, with higher strengths carrying higher regular prices. For eligible Medicare Part D beneficiaries, the Medicare GLP-1 Bridge began July 1, 2026. CMS states a $50 monthly supply cost through December 31, 2027. It is a limited demonstration with clinical and enrollment criteria, and people who otherwise have Part D access are not eligible simply because their plan does not list a medicine on its formulary.

Maintenance and stopping need a plan

Weight regain after stopping is common, which is why access and affordability deserve attention before treatment begins. In the STEP 1 extension, people who stopped semaglutide regained an average 11.6 percentage points of lost weight during the following year, roughly two-thirds of the loss achieved during treatment. That finding does not mean a person must stay on treatment forever. It does mean a forced stop because of cost, coverage, a pharmacy delay, side effects, or a life change can be difficult. Discussing maintenance, monitoring, and alternatives before a disruption gives a clinician more room to help.

Safety and compounded product limits

FDA-approved labels list gastrointestinal side effects and warnings involving gallbladder disease, pancreatitis, dehydration-related kidney problems, and low blood sugar when some diabetes medicines are used at the same time. They also tell people to inform care teams about planned surgery or deep sedation. Wegovy and Zepbound labels carry boxed warnings about thyroid C-cell tumors seen in rodents and list contraindications involving a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. On January 13, 2026, FDA asked manufacturers to remove suicidal behavior and ideation language from certain GLP-1 weight-management labels after finding no increased risk. That change does not replace attention to mental health symptoms or a person's history. FDA says compounded drugs do not undergo its premarket review for safety, effectiveness, or quality. By May 31, 2026, FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. Reports cannot show how often a problem occurs or prove that a product caused it, but they are a reason to use a licensed prescriber and state-licensed pharmacy and to avoid products sold as research use only or not for human consumption.

Questions to take to a clinician or pharmacist

Bring a short record to appointments: current medicines and supplements, past medicine experiences, insurance information, refill dates, out-of-pocket costs, and symptoms such as nausea, constipation, diarrhea, appetite changes, and hydration. If blood sugar is monitored, bring those readings as well. A simple log can make it easier to tell whether a problem is access, cost, side effects, or a medicine question that needs follow-up.